Repeatability of health economic data in COPD  by Nielsen, Rune et al.
Respiratory Medicine (2008) 102, 1556e1562ava i lab le a t www.sc iencedi rec t .com
journa l homepage : www.e lsev ie r . com/ loca te / rmedRepeatability of health economic data in COPDRune Nielsen a,*, Ane Johannessen b, Hege Marie Schnelle a, Per S. Bakke a,c,
Jan E. Askildsen d,e, Ernst R. Omenaas a,b, Amund Gulsvik a,ca Institute of Medicine, University of Bergen, Haukeland University Hospital, N-5021 Bergen, Norway
b Centre for Clinical Research, Haukeland University Hospital, N-5021 Bergen, Norway
c Department of Thoracic Medicine, Haukeland University Hospital, N-5021 Bergen, Norway
d Department of Economics, University of Bergen, N-5007 Bergen, Norway
e The Rokkan Centre, University of Bergen, N-5015 Bergen, Norway
Received 7 April 2008; accepted 12 June 2008
Available online 31 July 2008KEYWORDS
Healthcare costs;
Chronic obstructive
pulmonary disease;
Reproducibility of
results;
Repeatability;
Reliability* Corresponding author. Tel.: þ47 5
(mobile); fax: þ47 55 97 51 49.
E-mail address: rune.nielsen@med
0954-6111/$ - see front matter ª 200
doi:10.1016/j.rmed.2008.06.008Summary
Background: Little is known concerning the precision of self-reported health economic data.
Aim: To investigate the repeatability of self-reported health economic cost and utilization
data in subjects with chronic obstructive pulmonary disease (COPD).
Methods: Twelve weeks after inclusion, a physician and a nurse in random order interviewed
29 subjects with post-bronchodilator COPD included from a research registry of COPD patients.
The interview recorded healthcare utilization and costs, sick leave, exacerbations and quality
of life (QoL). Variation of individual agreement of observations was described estimating kappa
statistics and 95% limits of agreement.
Results: Mean age was 63 years (standard deviation (SD) 10) and 17 participants were men. Av-
erage FEV1% predicted was 56% (SD 15). For sick leave, exacerbation, healthcare provider visit,
change of medication, assistance and leisure time the kappa values were 1.00, 0.73, 0.73,
0.66, 0.63 and 0.54, respectively. The physician recorded fewer days of exacerbation and
fewer contacts with healthcare providers than the nurse (pZ 0.01 and pZ 0.05, respectively).
The 95% limits of agreement for costs of drugs were 690 to þ710 Norwegian Kroner (NOK),
1200 to þ899 NOK for costs of healthcare providers and 20 to þ26 for QoL as measured
by a visual analogue scale.
Conclusion: Repeatability of economic data from COPD patients showed considerable varia-
tion. This issue should be addressed when analyzing cost data from interviews and when
designing studies on health economy.
ª 2008 Elsevier Ltd. All rights reserved.5 97 30 79, þ47 932 56 907
.uib.no (R. Nielsen).
8 Elsevier Ltd. All rights reservedIntroduction
Chronic obstructive pulmonary disease (COPD) is a globally
widespread disease, causing considerable morbidity and.
Figure 1 Design of a study of the repeatability of health eco-
nomic data in COPD patients.
Repeatability of health economic data 1557mortality.1,2 In terms of economic impact, COPD imposes
a large burden on the society as well as on the individual.3,4
COPD cost studies are usually based on register informa-
tion,5 or information provided by the patients themselves.3
Register-based data are already available for large popula-
tion groups.5,6 However, they cover only part of the true
costs related to the disease. For instance are costs for
help from unprofessional caregivers and over-the-counter-
medication often ignored, and subjects without a physician
diagnosis are not included.3 Self-reported information
allows access to detailed personal costs, and thus cost esti-
mates contain different information than those of register-
based studies. However, the quality of self-reported cost
information by COPD patients has hardly been examined.
The validity of self-reported economic data has been
compared to register data, showing that self-reports of
hospital admissions are of higher validity than reports on
healthcare provider contacts, and that the ability of
patients to recall drug use may be unsatisfactory.7 No infor-
mation is available regarding the repeatability of cost items
provided by patients in economic surveys. Such knowledge
is important when interpreting the overall validity of health
economic data on COPD.
In a pilot study of the economics of COPD in Norway, we
evaluated questionnaires used in collecting data on health-
care utilization. The aim was to investigate the quality of
self-reported health economic data as measured by the
repeatability between two interviewers.
Material and methods
The study was conducted between December 2004 and
March 2005. At baseline 30 COPD patients performed
a post-bronchodilator spirometry. Twelve weeks later,
subjects were in random order, twice interviewed by
telephone by a physician and a nurse using the same
questionnaire. Time interval between the two interviews
was at least 3 days (mean 6 days, range 3e14 days). A flow
chart of the design is shown in Fig. 1. The Regional Commit-
tee for Medical Research Ethics of Western Norway
approved the study.
Study population and sample
From a list of 40 COPD patients in a research registry,
fulfilling a set of inclusion criteria, participants were
recruited by telephone until 30 subjects had accepted the
invitation and signed the informed consent. Four partici-
pants were not reached by phone, six refused participation
because of disease and upcoming Christmas holidays.
There were three inclusion criteria. Firstly, all subjects
were 40 years of age or above. Secondly, all participants
had to be current or former smokers with a minimum of 2.5-
pack years tobacco exposure. Thirdly, all participants had
COPD GOLD stage 2 or more severe.8
Methods
A group of five physicians in pulmonary medicine and two
health economists developed the interview questionnaires.
Several questions were imported from the OLIN cost-of-illnessstudy.9 Questions were added from the Hordaland County
Respiratory Health Survey questionnaire.10 Quality of life
(QoL) was registered using the Euroqol five dimensional
questionnaire (EQ-5D) and visual analogue scale (VAS).11
Each participant was interviewed with the same ques-
tionnaire on two occasions. Subjects were not informed at
the first interview that there was going to be a second one.
The sequenceof interviewerswasdecidedby randomization.
The two interviewers were both 27 years old. The nurse
was female, and the physician was male. The nurse had
worked 2.5 years in the Department of Thoracic Medicine at
Haukeland University Hospital. The physician had com-
pleted Medical School, but not his internship.
Variables
The 12 weeks surveillance questionnaire on costs of COPD
comprised 12 separate sections covering disease activity,
healthcare utilization, costs of COPD and QoL. Six categor-
ical variables had five or more positive outcomes. Positive
answers for categorical variables were also recorded for
home oxygen treatment (2), pulmonary rehabilitation (2),
changed job situation (2), change of profession (1), hospi-
talization due to COPD (1), hospitalization due to other
conditions (1), complementary medicine (1), change of
residence (1) and having a nebulizer at home (1).
The six categorical variables and five continuous core
variables were as follows. (1) Exacerbation, defined as self-
reported worsening of two major symptoms (dyspnoea, in-
creased sputum, changed colour of sputum), or one major
symptom and any of the minor symptoms (runny/stuffed
nose, wheezing, sore throat/cough, asthenia) (modified af-
ter Ref.12). (2) Exacerbation days, defined as the number of
days spent in exacerbation. (3) Medication change, defined
as any change in medication, any intermittent courses or
use of over-the-counter-medication during the last 12
Table 1 Characteristics of 29 participants with COPD
GOLD stage 2 and above by interviewer in first follow-up
interview
(N ) Physician
(15)
Nurse
(14)
Total
(29)
Male, n (%) 9 (60) 8 (57) 17 (59)
Age
40e59 years, n (%) 9 (60) 7 (50) 16 (55)
60e79 years, n (%) 5 (33) 6 (43) 11 (38)
80 years, n (%) 1 (7) 1 (7) 2 (7)
Smoking habits
Current smoker 6 (40) 8 (57) 14 (48)
Ex-smoker 9 (60) 6 (43) 15 (52)
Packyears, mean (SD) 30 (18) 29 (18) 30 (17)
Education
Primary school 4 (27) 3 (21) 7 (24.)
High school 9 (60) 9 (64) 18 (62)
University 2 (13) 2 (14) 4 (14)
Post-BD FEV1% of predicted
50e80% 10 (67) 9 (64) 19 (69)
< 50% 5 (33) 5 (36) 10 (31)
Mean (SD) 58 (15) 54 (16) 56 (15)
Dyspnoea on walking 2
flights of stairs, n (%)
11 (73) 12 (86) 23 (79)
Chronic cough, n (%) 8 (53) 9 (64) 17 (59)
Table 2 Incidence of events by 12 weeks, percent agree-
ment and Cohen’s Kappa of two interviewers
Incidence
in 29
interviews
by physician
(%)
Incidence
in 29
interviews
by nurse
(%)
Percent
agreement
(%)
Cohen’s
Kappa
Change of
medication
79 67 86 0.66
Exacerbation 55 55 86 0.73
Healthcare
provider visit
41 55 86 0.73
Sick leavea 33 33 100 1.00
Leisure time
loss >5 h
per week
34 34 79 0.54
Assistance at
home
28 44 83 0.63
a Sick leave for 15 subjects in employment.
1558 R. Nielsen et al.weeks (irrespective of cause). (4) Costs of drugs were inter-
viewer-recorded total costs of medication. (5) Healthcare
provider visits recorded for ‘‘asthma, COPD or worsening
of respiratory symptoms’’. (6) Number of contacts e a sum-
mation of all healthcare provider contacts (telephone,
home visits, office visits). (7) Costs of contacts defined as
interviewer-recorded total costs for all healthcare provider
contacts. (8) Sick leave recorded for subjects in a paid job
only, and only as due to ‘‘asthma, COPD or worsening of re-
spiratory symptoms’’. (9) Assistance e help from home
nursing services, housekeepers, family members or friends,
or dinner delivery. (10) Loss of leisure time defined as more
than 5 h lost per week due to ‘‘asthma, COPD or worsening
of respiratory symptoms.’’ (11) VAS e the answer per tele-
phone to the specific EQ-5D VAS question. See Appendix for
questionnaire texts.
Statistics
From the 12 weeks interviews we chose to only analyze
categorical variables with at least five positive outcomes,
as few outcomes give less precision of estimates, and also
Pearson Chi-Square requires at least five events in each
cell.13 When continuous variables were missing due to
negative answers on entry questions, the variables were
recoded to zero.
Frequencies were compared using chi-square tests and
tests of equality of proportions. Means were compared
using t-tests after assessing normality. Testeretest agree-
ment for continuous outcomes was described using methods
outlined by Bland and Altman.14 This method implies gener-
ating the ‘‘95% limits of agreement’’ from the mean differ-
ence between two measurements and its standard
deviation. The limits of agreement are illustrated by plot-
ting the difference between two observations against the
mean of the same observation differences. For categorical
outcomes we have computed kappa values, classified ac-
cording to Landis and Koch.15
For all analyses p-values less than 0.05 were considered
significant. All analyses were performed using Stata 9.2 for
Windows (Stata Corp, College Station, TX).
Results
One participant withdrew the day after being included. The
remaining 29 subjects completed the protocol (Table 1).
The mean age (SD) was 63 (10) years, 59% were men and
48% were current smokers. The mean FEV1 (SD) predicted
was 56 (15)% (15), and 83% of the participants had either
chronic cough or dyspnoea when climbing two flights of
stairs or had more severe dyspnoea. There were no signifi-
cant differences in any of the baseline characteristics of
the participants when comparing proportions and averages
by first interviewer.
Categorical outcomes
The average incidence of events per 12 weeks of the
analyzed categorical variables varied from 33% to 75%. No
significant difference in incidence was observed between
the physician and the nurse (Table 2). Kappa values for lossof leisure time showed moderate agreement (0.54), while
exacerbation status, healthcare provider visits, change of
medication and assistance showed substantial agreement
(0.73, 0.73, 0.66 and 0.63, respectively). For sick leave
the agreement was perfect.
When comparing the testeretest between first and
second interview (that is, independent of interviewer),
similar kappa values as above were obtained.
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For continuous variables (Table 3), the differences accord-
ing to the interviewers were significant for exacerbation
days (pZ 0.01) and borderline significant for number of
healthcare provider contacts (pZ 0.05). BlandeAltman
plots show that the width of the 95% limits of agreement
was 2100 Norwegian Kroner (NOK, V 255) for self-reported
costs of healthcare provider contacts, 1400 NOK (V 170) for
drug costs, 32 days for length of exacerbation, nine con-
tacts with healthcare providers and 46 units on the EQ-5D
VAS (Fig. 2). The large ranges of values for number and
costs of healthcare provider contacts were attributable to
one participant reporting eight visits to a chiropractor
due to obstructive lung diseases, which were taken into ac-
count by only one interviewer.
Aiming to investigate effects of the interviewer-order
we first stratified the sample according to first interviewer
and compared information recorded by the physician with
information recorded by the nurse (Table 4). This showed
that the difference between reported number of days in ex-
acerbation to the physician and to the nurse was significant
only when the physician conducted the first interview. The
effect of interviewer-order was also investigated by looking
at intra-observer effects. We then found significant lower
average cost of healthcare provider contacts in the group
first interviewed by the physician compared to the group
where the physician conducted the second interview (NOK
33.7 vs. NOK 157.1, p< 0.05, Table 4). No significant differ-
ences were observed for the other continuous outcomes in
these analyses.
When comparing the testeretest between first and
second interview (that is, independent of interviewer) no
significant differences were observed. The widths of the
95% limits of agreement did not change by any substantial
degree (results not shown).Table 3 Comparison of repeated measurement of continuous o
Range Mean
Healthcare provider contacts
Physician 0e4 0.6
Nurse 0e12 1.4
Costs: healthcare
providers (NOKa) Physician 0e620 93
Nurse 0e2 740 268
Costs: drugs (NOKa)
Physician 0e2 500 556
Nurse 0e3 300 546
EQ-5D VASb
Physician 35e90 67
Nurse 30e90 64
Exacerbation days
Physician 0e40 7
Nurse 0e60 11
a NOK: Norwegian Kroner, 8.24 NOKZ 1 V (www.norgesbank.no 31.
b VAS: visual analogue scale.Discussion
This study indicates that repeated measurements of cate-
gorical variables on self-reported exacerbation and health-
care utilization in COPD patients show substantial
agreement (Cohen’s kappa> 0.6). For self-reported costs
there were no significant differences between the two
measurements, but we observed wide 95% limits of agree-
ment. Number of days with exacerbation and number of
healthcare provider contacts were lower when recorded
by a physician than by a nurse. When analyses were con-
ducted comparing two interviews at a different time irre-
spective of observer, no systematic differences were
found. To our knowledge this is the first study reporting re-
peatability of cost items derived from patients’ self-
reports.
Some methodological considerations are needed. Firstly,
our findings were from a study with only 29 participants.
The frequency of services like hospital admissions, home
oxygen treatment and pulmonary rehabilitation was low,
and we chose to emphasize events with an incidence of at
least 17% (five out of 29 participants) per 12 weeks. The
interviewers were of different professional background and
sex. This might lead to different responses from the
attendants.16 A larger study, with more participants and in-
terviewers would allow a more complete examination of in-
terviewer effects. This would also enable multivariate
analyses comparing possible predictors of disagreement
like gender, age, socioeconomic status and severity of
disease.
Secondly, the median time between the first and the
second interview was 6 days. Some participants might have
remembered their answer to the first interviewer. However,
participants were not made aware of the upcoming second
interview. Investigators of respiratory symptoms10 and en-
vironmental exposures17 have used shorter10 and longer17utcomes according to interviewer
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Figure 2 BlandeAltman plots for number of days with exacerbation (A), number of visits to health care providers (B), costs of
drugs (C), costs of health care provider visits (D) and quality of life on a visual analogue scale (E). On the X-axis the average of
the two measurements is shown, while on the Y-axis the difference between the same two measurements are plotted. The brack-
eted lines show the 95% limits of agreement.
1560 R. Nielsen et al.time intervals when examining retest agreement, both re-
vealing considerable variation.
Thirdly, our participants were recruited from a popula-
tion with a rather large proportion of subjects with FEV1% of
predicted below 50%. This would imply high consumption of
healthcare resources, compared with a healthier group. Re-
membering ‘‘zero utilization’’ might be easier than recall-
ing how many visits were utilized the last 12 weeks in the
present group. Validity studies have indicated decreased
validity when excluding non-utilizing subjects.18,19 StudyingTable 4 Comparison of information in interviews by a physicia
First interview by physician (NZ
Nurse interview Physician interv
Healthcare provider
contacts, mean (SE)
1.60 (0.82) 0.33 (0.16)
Costs: healthcare
providers (NOK), mean (SE)
284.7 (181.2) 33.7 (19.3)
Costs: drugs (NOK) 529.9 (214.2) 525.6 (184.2)
EQ-5D VAS, mean (SE) 63.3 (5.0) 65.3 (4.9)
Exacerbation days,
mean (SE)
13.2 (4.6) 7.6 (3.2)
Stratified according to which conducted the first interview.
p-Values from paired t-test of difference. NOK e Norwegian Kroner,
analogue scale. SE e standard error.a population with lower morbidity might have resulted in
higher repeatability.
Most literature on the validity of health economic self-
reported data is comparisons to register-based information,
with the latter as a gold standard. In a review of 47 studies,
Evans et al.7 listed four factors as main determinants of
agreement. First the elapsed time for which the patient
was to recollect information e the shorter the more accu-
rate. Second, more salient events as hospitalizations are
more likely to be remembered than, e.g. intermittentn and a nurse
15) First interview by nurse (NZ 14)
iew p-Value Nurse interview Physician interview p-Value
0.11 1.29 (0.44) 0.93 (0.32) 0.29
0.17 249.6 (116.0) 157.1 (54.0) 0.33
0.97 564.1 (134.5) 589.6 (167.9) 0.76
0.59 64.3 (3.6) 67.9 (2.7) 0.14
0.029 9.0 (3.7) 6.9 (2.2) 0.27
8.24 NOKZ 1 V (www.norgesbank.no 31.12.2004). VAS e visual
Supplementary information
Supplementary data associated with this article
can be found, in the online version, at
doi:10.1016/j.rmed.2008.06.008
Repeatability of health economic data 1561courses of antibiotics. Third, socially unacceptable behav-
ior as smoking is less likely to be reported. Other factors
listed by Evans et al. as possible confounding variables
were high age, low socioeconomic status and reduced men-
tal health. In line with this, our findings might not be appli-
cable in a population with different characteristics. The
time period of 12 weeks was chosen, as this is practically ap-
plicable. With longer periods the risk of recall bias increases
and shorter intervals one would need more interviews and
thus the study would be more costly. Contacts with health-
care providers and changes of medication are non-salient
events, and numbers of days with specifically defined symp-
toms (exacerbations) are difficult to recall for subjects with
many respiratory symptoms. However, as Ritter and co-
workers have shown, self-reports may in a diseased popula-
tion be more sensitive than registers, because the recordings
of healthcare services will be more complete.20
The repeatability of categorical data, judged by kappa
statistics, was substantial. Kappa statistics are sensitive to
frequency of events,21 which makes comparison between
studies and between different variables difficult. In our
study, the two items with the lowest kappa values (loss of
leisure time and assistance at home) were among the vari-
ables with lowest incidence (Table 2). Other investigators
have shown similar trends for prevalence of respiratory
symptoms.10 The kappa values of sick leave and leisure
time loss (1.00 and 0.54, respectively) with similar inci-
dences, indicate that sick leave give more valid information
than leisure time loss.
BlandeAltman methods describe the variability between
repeated observations of continuous data, but leaves to the
clinical investigator to decide if the limits of agreement are
acceptable or not.13 The physician recorded exacerbation
days and number of healthcare provider contacts differ-
ently than the nurse. This might be a difference of individ-
ual interviewing style, but also might be attributed to
subjects understating their disease when talking to a physi-
cian.22 The days in exacerbation and number of healthcare
provider contacts should be interpreted with caution with
regard to precision of the estimates. If patients were asked
about all contacts and specified the cause of these, omis-
sion of contacts due to misclassification of cause could
have been avoided. The difference for drugs costs might
have resulted from one interviewer recording drugs for
other diseases than COPD while the other interviewer did
not. If the differences in recordings of costs were extrapo-
lated to annual costs the widths of the 95% limits of agree-
ment would reach 8900 NOK (V 1080) per patient for the
healthcare provider visits, and 6000 NOK (V 728) per
patient for the drugs costs.
The present findings were used to develop a protocol for
a large COPD cost-of-illness study in Norway, EconCOPD.
For EconCOPD we plan to use official registry information
for drug use and hospital admissions. All patients will be
asked to bring their prescription drugs to the phone for
follow-up interviews. We will hire nine interviewers to
reduce vulnerability to individual interview style. Compre-
hensive written guidelines will be developed, and all in-
terviewers will go through extensive training including
lectures, role-plays and supervised interviews on COPD
patients. The dangers of observer effects will be emphasized
throughout the entire survey. To increase precision ofestimates of low incidence events a large fraction of
severely ill COPD patients will be recruited.
In summary, we found that the repeatability of frequent
self-reported categorical events was acceptable in a health
economic pilot survey of COPD patients. However, the
physician recorded number of days in exacerbation and
number of healthcare provider contacts differently than
the nurse. The width of the 95% limits of agreement was
large for reports on the patients’ own financial expenses.
This knowledge is important for researchers interpreting
cost-of-illness studies and measures need to be taken to
minimize the inter-observer effects.
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